NCT06637332 Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
| NCT ID | NCT06637332 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Todd C. Lee MD MPH FIDSA |
| Condition | Staphylococcus Aureus Septicemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-11-14 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 300 participants in total. It began in 2024-11-14 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Eligibility Criteria
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria: Inclusion Criteria: * Methicillin-resistant S. aureus bacteremia Exclusion Criteria: * Severe allergy or non-severe rash to vancomycin or daptomycin * Suspected or confirmed MRSA pneumonia * Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Contact & Investigator
Todd C Lee, MD MPH FIDSA
PRINCIPAL INVESTIGATOR
McGill University Health Centre/Research Institute of the McGill University Health Centre
Frequently Asked Questions
Who can join the NCT06637332 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Staphylococcus Aureus Septicemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06637332 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06637332 currently recruiting?
Yes, NCT06637332 is actively recruiting participants. Contact the research team at lina.petrella@muhc.mcgill.ca for enrollment information.
Where is the NCT06637332 trial being conducted?
This trial is being conducted at Concord, Australia, Newcastle, Australia, Westmead, Australia, Herston, Australia and 11 additional locations.
Who is sponsoring the NCT06637332 clinical trial?
NCT06637332 is sponsored by Todd C. Lee MD MPH FIDSA. The principal investigator is Todd C Lee, MD MPH FIDSA at McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 300 participants.